For nearly two decades, UCSF Bioengineering professor Shuvo Roy, PhD, William Fissell, MD, and David Humes, MD, have been developing an implantable bioartificial kidney as an alternative treatment for end-stage renal disease. Under the guidance of FDA and a new expedited regulatory plan, the team has completed two years of preclinical testing and plans to move into humans in early 2018 and gain regulatory approval by 2020.
Silicon isn't just for computers. It can make a pretty good kidney, too.
The UCSF-Stanford Pediatric Device Consortium is funded by the U.S. Food & Drug Administration's Office of Orphan Products Development under grant no. P50FD007967.
